References
1. Algorithms of specialized medical care for patients with diabetes mellitus. 10th edition (expanded). In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). Moscow, 2021. DOI: https://doi.org/10.14341/DM12802 (in Russian)
2. Colosia A.D., Palencia R., Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013; 6: 327–38. DOI: https://doi.org/10.2147/DMSO.S 51325
3. Bansilal S., Farkouh M.E., Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007; 99 (4A): 6B–14B. DOI: https://doi.org/10.1016/j.amjcard.2006.11.002
4. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (2): 104–12. DOI: https://doi.org/10.14341/DM2004116-17 (in Russian)
5. Ling J., Montvida O., Khunti K., et al. Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: Real-world evidence from primary care. Diabetes Obes Metab. 2021; 23 (7): 1518–31. DOI: https://doi.org/10.1111/dom.14364
6. Paul S.K., Klein K., Thorsted B.L., Wolden M.L., Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015; 14: 100. DOI: https://doi.org/10.1186/s12933-015-0260-x
7. Nanjan M.J., Mohammed M., Kumar B.R., Chandrasekar M.J.N. Thiazolidinediones as antidiabetic agents: a critical review. Bioorg Chem. 2018; 77: 548–67. DOI: https://doi.org/10.1016/j.bioorg.2018.02.009
8. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356 (24): 2457–71. DOI: https://doi.org/10.1056/NEJMoa072761
9. Dormandy J.S., Charbonnel B., Eckland D., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366 (9493): 1279–89. DOI: https://doi.org/10.1016/S-0140-6736(05)67528-9
10. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I.; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001; 86 (1): 280–8. DOI: https://doi.org/10.1210/jcem.86.1.715
11. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al.; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28 (7): 1547–54. DOI: https://doi.org/10.2337/diacare.28.7.1547 PMID: 15983299
12. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000; 23 (11): 1605–11. DOI: https://doi.org/10.2337/diacare.23.11.160
13. Davies M.J., Aroda V.R., Collins B.S., Gabbay R.A., Green J., Maruthur N.M., et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45 (11): 2753–86. DOI: https://doi.org/10.2337/dci22-0034
14. ElSayed N.A., Aleppo G., Aroda V.R., Bannuru R.R., Brown F.M., Bruemmer D., et al.; on behalf of the American Diabetes Association. 3. Prevention or delay of type 2 diabetes and associated comorbidities: Standards of Care in Diabetes-2023. Diabetes Care. 2023; 46 (suppl 1): S 41–8. DOI: https://doi.org/10.2337/dc23-S-003
15. Diani A.R., Sawada G., Wyse B., Murray F.T., Khan M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004; 286 (1): E 116–22. DOI: https://doi.org/10.1152/ajpendo.00331.2003
16. Yin H., Park S.Y., Wang X.J., et al. Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin. PLoS One. 2013; 8 (6): e65777. DOI: https://doi.org/10.1371/journal.pone.0065777
17. Ishida H., Takizawa M., Ozawa S., et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism. 2004; 53 (4): 488–94. DOI: https://doi.org/10.1016/j.metabol.2003.11.021
18. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28 (7): 1547–54. DOI: https://doi.org/10.2337/diacare.28.7.1547
19. Tan M.H., Baksi A., Krahulec B., et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005; 28 (3): 544–50. DOI: https://doi.org/10.2337/diacare.28.3.544
20. Charbonnel B., Schernthaner G., Brunetti P., et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005; 48 (6): 1093–104. DOI: https://doi.org/10.1007/s00125-005-1751-1
21. Hanefeld M., Pfutzner A., Forst T., Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin. 2006; 22 (6): 1211–5. DOI: https://doi.org/10.1185/030079906X112598
22. Kahn S.E., Haffner S.M., Heise M.A., et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355 (23): 2427–43. DOI: https://doi.org/10.1056/NEJMoa066224
23. Erdmann E., Dormandy J., Charbonnel B., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007; 49 (17): 1772–80. DOI: https://doi.org/10.1016/j.jacc.2006.12.048
24. Wilcox R., Bousser M., Betteridge D.J., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38 (3): 865–73. DOI: https://doi.org/10.1161/01.STR.0000257974.06317.49
25. De Jong M., Vander Worp H.B., Vander Graaf Y., et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017; 16 (1): 134. DOI: https://doi.org/10.1186/s12933-017-0617-4
26. Spence J.D., Viscoli C.M., Inzucchi S.E., et al. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol. 2019; 76 (5): 526–35. DOI: https://doi.org/10.1001/jamaneurol.2019.0079
27. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. 2006; 296 (21): 2572–81. DOI: https://doi.org/10.1001/jama.296.21.joc60158
28. Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115 (4): 459–67. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.628875
29. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005; 112: 2792–8.
30. Nishio K., Sakurai M., Kusuyama T., et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006; 29: 101–6.
31. Riche D.M., Valderrama R., Henyan N.N. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care. 2007; 30: 384–8.
32. DeFronzo R.A., Inzucchi S., Abdul-Ghani M., Nissen S.E. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019; 16 (2): 133–43. DOI: https://doi.org/10.1177/1479164118825376
33. Schernthaner G., Matthews D.R., Charbonnel B., et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004; 89 (12): 6068–76. DOI: https://doi.org/10.1210/jc.2003-030861
34. Mudaliar S., Chang A.R., Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003; 9: 406–16. DOI: https://doi.org/10.4158/EP.9.5.406
35. Guan Y., Hao C., Cha D.R., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005; 11: 861–6. DOI: https://doi.org/10.1038/nm1278
36. Kasliwal R., Wilton L.V., Shakir S.A. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf. 2008; 31: 839–50. DOI: https://doi.org/10.2165/00002018-200831100-00003
37. Eldor R., DeFronzo R.A., Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care. 2013; 36 (suppl 2): S 162–74. DOI: https://doi.org/10.2337/dcS-13-2003
38. Clarke G.D., Solis-Herrera C., Molina-Wilkins M., et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care. 2017; 40 (11): 1530–6. DOI: https://doi.org/10.2337/dc17-0078
39. Erdmann E., Charbonnel B., Wilcox R.G., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007; 30 (11): 2773–8. DOI: https://doi.org/10.2337/dc07-0717
40. Charbonnel B.H., Matthews D.R., Schernthaner G., et al. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005; 22 (4): 399–405. DOI: https://doi.org/10.1111/j.1464-5491.2004.01426.x
41. Dormandy J., Bhattacharya M., van Troostenburg de Bruyn A.R.; PROactive Investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009; 32 (3): 187–202. DOI: https://doi.org/10.2165/00002018-200932030-00002
42. Rosenstock J., Inzucchi S.E., Seufert J., Fleck P.R., Wilson C.A., Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010; 33 (11): 2406–8. DOI: https://doi.org/10.2337/dc10-0159
43. Bosi E., Ellis G.C., Wilson C.A., Fleck P.R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, doubleblind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011; 13 (12): 1088–96. DOI: https://doi.org/10.1111/j.1463-1326.2011.01463.x
44. DeFronzo R.A., Burant C.F., Fleck P., Wilson C., Mekki Q., Pratley R.E. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97 (5): 1615–22. DOI: https://doi.org/10.1210/jc.2011-2243
45. Kim H.J., Jeong I.K., Hur K.Y., et al. Comparison of efficacy of glimepiride, alogliptin, and alogliptin-pioglitazone as the initial periods of therapy in patients with poorly controlled type 2 diabetes mellitus: an open-label, multicenter, randomized, controlled study. Diabetes Metab J. 2022; 46 (5): 689–700. DOI: https://doi.org/10.4093/dmj.2021.0183